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Aims: We explored people’s reasons for, and experiences of, using bolus advisors to deter-
mine insulin doses; and, their likes/dislikes of this technology.
Subjects and methods: 42 people with type 1 diabetes who had received instruction in use of
bolus advisors during a structured education course were interviewed post-course and 6
months later. Data were analysed thematically.
Results: Participants who considered themselves to have poor mathematical skills
highlighted a gratitude for, and heavy reliance on, advisors. Others liked and chose to
use advisors because they saved time and effort calculating doses and/or had a data storage
facility. Follow-up interviews highlighted that, by virtue of no longer calculating their doses,
participants could become deskilled and increasingly dependent on advisors. Some forgot
what their mealtime ratios were; others reported a misperception that, because they were
pre-programmed during courses, these parameters never needed changing. Use of data
storage facilities could hinder effective review of blood glucose data and some participants
reported an adverse impact on glycaemic control.
Discussion: While participants liked and perceived benefits to using advisors, there may be
unintended consequences to giving people access to this technology. To promote effective
use, on-going input and education from trained health professionals may be necessary.
# 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Contents available at ScienceDirect
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and Clinical Practice
journal homepage: www.elsevier.com/locate/diabres1. Introduction
Flexible intensive insulin therapy (FIIT) is now widely used in
the management of type 1 diabetes [1]. For people using* Corresponding author at: Centre for Population Health Sciences, Me
Tel.: +44 131 650 6197; fax: +44 131 650 6902.
E-mail address: j.lawton@ed.ac.uk (J. Lawton).
1 See Appendix A for the list of REPOSE Group members.
http://dx.doi.org/10.1016/j.diabres.2014.09.011
0168-8227/# 2014 The Authors. Published by Elsevier Ireland Ltd. This
creativecommons.org/licenses/by-nc-nd/3.0/).multiple daily injections (MDI), FIIT comprises long-acting
basal insulin injected once or twice daily, and quick acting
bolus insulin adjusted according to blood glucose levels and
carbohydrate intake at meals. Similar principles are utilised in
pump therapy in which the pump infuses a constant basal ratedical School, University of Edinburgh, Edinburgh EH8 9AG, UK.
 is an open access article under the CC BY-NC-ND license (http://
Box 1. Instruction and education received during DAFNE
courses on REPOSE Trial
During their 5 day courses, participants were:
 Taught how to count carbohydrates (expressed as 10-g
carbohydrate portions) and calculate mealtime insulin
dose requirements as ratios to the number of carbo-
hydrate portions consumed.
 Required to undertake regular review of self-monitor-
ing of blood glucose readings (normally taken pre-
meal and pre-bed) and instructed how to interpret
patterns and/or changes in readings to calculate and
adjust mealtime ratios and insulin dose requirements
to meet or maintain pre-prandial and bedtime targets.
 Given instruction on how to calculate and use correc-
tive insulin or additional carbohydrate portions to help
maintain blood glucose readings within recom-
mended target ranges (5.5–7.5 mmol/l before break-
fast, 4.5–7.5 mmol/l before other meals, 6.5–8.0
mmol/l before bed in the DAFNE programme).
 Encouraged to undertake mathematical calculations
mentally for the first two days so that when the bolus
advisers were introduced and programmed under the
supervision of the course Educators using a trial stan-
dard operating procedure (SOP) on day three, individ-
uals could make informed judgements about the
advisor calculations for the remainder of the week
and begin to make alterations to their personalised
settings where relevant.
 Courses were normally delivered by two experienced
DAFNE Educators – a diabetes specialist nurse and a
dietitian.
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 0 6 ( 2 0 1 4 ) 4 4 3 – 4 5 0444over 24 h, with patient-activated boluses to cover meals/
snacks and to correct high blood glucose. Many people do not
determine their bolus doses correctly, which may result in
persistent hypoglycaemia and/or hyperglycaemia [2,3] and
poor numeracy skills have been implicated [4,5]. Manually
calculating bolus doses can be complex and challenging as
individuals need to consider various parameters, including
their current blood glucose reading, quantity of carbohydrate
to be consumed, insulin sensitivity, insulin-to-carbohydrate
ratio and target blood glucose. Hence, people who lack
numeric skills may resort to guesswork, empirical estimates
or even to reinstating fixed prandial doses [5–8].
To aid determination of bolus doses, automated bolus
advisors are increasingly being used [7]. These provide
recommendations for mealtime and correction boluses based
on an individual’s current blood glucose reading, planned
carbohydrate intake and individualised, patient-specific pa-
rameters which are pre-programmed in (e.g. an individual’s
mealtime insulin-to-carbohydrate ratios, insulin sensitivity
and blood glucose targets), as well as taking into account
the previous insulin dose. Hence, for dose adjustment advice
to be accurate, the correct parameters must be used, and it
may take time for individuals’ insulin-to-carbohydrate ratios
and insulin sensitivity to be established. Furthermore, as
insulin sensitivity may change (e.g. due to pregnancy, weight
loss/gain, changes in physical activity patterns) the ratios
required to determine mealtime and corrective boluses may
need to be altered over time [5]. Hence regular review of blood
glucose readings and other data is essential to ensure the
correct parameters are used.
Research suggests that bolus advisors can lead to short-
term improvements in pre-prandial [9] and post-prandial
blood glucose levels in pump users [8,9], with a pilot trial
involving MDI users observing improved glycaemic control
maintained over 12 months [10] and a more recent RCT finding
improved glycaemic control at 26 weeks [11]. Improved
treatment satisfaction has also been observed amongst bolus
advisor users [9,11,12], which has been attributed to reduced
burden and stress because individuals are not required to
perform complicated mathematical calculations [12,13]. Sur-
veys have also found increased confidence in bolus calcula-
tion, improved ability to control blood glucose levels and
improved overall wellbeing amongst advisor users [6,13].
While research has focused on clinical and psychological
issues, little is known about how people with type 1 diabetes
actually use bolus advisors in their everyday lives, their likes
and dislikes of this technology, and whether, how, and why,
their use of bolus advisors may change over time. In this paper
we report findings from a qualitative investigation in which
we interviewed participants in a randomised controlled trial
which compared people with type 1 diabetes using MDI and
pumps respectively – the REPOSE (Relative Effectiveness of
Pumps Over MDI and Structured Education) Trial.
In the REPOSE Trial, participants were taught how to use
bolus advisors during a five day structured education course
(DAFNE – Dose Adjustment for Normal Eating [14]) – AccuChek1
Aviva Expert meters (Roche Diagnostics) in the case of MDI
participants and MiniMed Paradigm1 VeoTM Bolus Wizards1
(Medtronic) in the case of pump participants. See Box 1 for more
details about the instruction and education received.Following the courses, participants’ routine diabetes care
and clinical reviews were provided by their usual health care
providers. However, they were required to attend appoint-
ments at 6, 12 and 24 months in order for biomedical and
quantitative psychosocial data for the trial to be collected and
for data from metres and pumps to be downloaded. Educators
were also present at data collection clinics to provide support
and advice and to respond to any issues that arose during the
data collection process (e.g. for participants who were having
ongoing problems with glycaemic control, hypoglycaemia or
adverse events).
The aim of the qualitative research was to explore
participants’ experiences of using bolus advisors post course
and over time and their likes and dislikes of this technology.
The objectives were to aid interpretation of the findings of
clinical and psychological research (including the findings of
the REPOSE trial) and provide recommendations for support-
ing patients to use advisors effectively in the future.
2. Subjects and methods
2.1. Rationale for a qualitative design
Qualitative approaches are recommended when little is
known about the area of investigation [15,16]. Rather than
Box 2. Topics explored in the interviews
 Historical experiences of diabetes management and
health service contact (baseline interview).
 Perceived confidence/ability to undertake mathemati-
cal calculations (baseline and follow-up).
 Initial perceptions of bolus advisors (baseline); reasons
for choosing/not choosing to use advisor (baseline);
reasons for continuing or discontinuing use (follow-
up).
 Likes/dislikes of the advisor (baseline and follow-up);
changes in perceptions of advisors (follow-up).
 Everyday experiences of using advisor, reasons for
following/not following recommended doses; per-
ceived impact of using advisor on diabetes self-man-
agement (baseline and follow-up).
 Changes made to settings and individual parameters –
by whom, how, and why? (follow-up), contact with
health professionals (follow-up).
 Information and support needs to facilitate effective
use of advisors (baseline and follow-up).
 Recommendations for how advisor technology could
be improved (follow-up).
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hypothesis, qualitative approaches aim to open up and
explore new avenues of enquiry by using flexible, open-ended
approaches which allow participants to raise and discuss
the issues which they perceive as salient, including those
unforeseen at the study’s outset [15,16]. As such, qualitative
approaches provide a powerful and effective method of
uncovering and exploring people’s perspectives, understand-
ings and experiences; in this particular instance, their
experiences of using a bolus advisor. To do this in the current
study, a longitudinal design was employed, in which partici-
pants were interviewed within two weeks of completing their
DAFNE courses (baseline) and 6 months later. This design
enabled participants’ own understandings and experiences of
using bolus advisors to be captured and explored in-depth,
and any continuities and changes in their use of this
technology to be identified and explored.
2.2. Recruitment and sampling
Participants were recruited from seven REPOSE centres across
the UK with roughly equal numbers recruited from each
centre. When participants were consented to take part in the
trial, they were asked whether they would be willing to be
approached to participate in the qualitative research. Parti-
cipants who gave their agreement were purposively sampled
so that both pump and MDI users were interviewed and so
there was broad, and roughly equal representation of ages,
gender, diabetes duration and occupational/SES groups in the
final sample. Sampling was undertaken by the qualitative
research team who kept a recruitment log which was updated
weekly and who liaised with the trial team in order to select
participants for the qualitative study who met the required
sampling criteria.
2.3. Data collection
Recruitment and baseline interviews were staggered, to
allow for concurrent data collection and analysis, in line
with the principles of Grounded Theory research [17]. This
enabled issues arising in earlier interviews to be examined
and explored in-depth in later interviews. Interviews were
conducted at a time and in a location chosen by participants
(mostly their own homes). These interviews were informed
by topic guides which contained a series of open-ended
questions which helped to ensure the discussion remained
relevant to the study aims and objectives, whilst providing
the flexibility needed for participants to talk in depth, and in
their words, about their experiences. These topic guides
were developed in light of literature reviews, observation of
courses, input from course educators, and revised in light
of on-going data analysis. Relevant areas explored are
outlined in Box 2. The same topics were covered with all
participants. In addition, each person’s baseline account
was reviewed before their 6 month interview to enable
follow-up of specific issues raised by particular individuals.
Interviews averaged 1 h, were digitally recorded and
transcribed in full. Recruitment and data collection was
stopped when an on-going analysis of the data highlighted
that no new findings or themes were emerging from newinterviews. Interviews were conducted between June 2012
and June 2013.
2.4. Data analysis
A thematic analysis was undertaken by two experienced
qualitative researchers (J.L. and J.K.) who independently
reviewed all data before attending regular meetings to
compare their interpretations and reach agreement on
recurrent themes and findings. Each individual’s baseline
and 6 month interview was compared, and attention was
paid to any continuities and changes in their use of bolus
advisors over time, and the reasons for these. Participants’
longitudinal accounts were also compared and contrasted,
enabling the identification of overarching themes which cut
across different people’s experiences [18]. Initially, the
interviews with MDI and pump users were treated as two
distinct datasets and subjected to comparative analyses to
see if there were any differences in the experiences reported
by the two groups. However, as the main issues and
experiences reported by participants were found to be the
same in both groups, the two datasets were combined in
the final analysis. The final coding frame, which reflected
the original questions and emergent themes, was developed
once all data had been reviewed and consensus reached on
key themes and findings. NVivo9, a qualitative software
package, was used to facilitate data coding/retrieval.
The REPOSE clinical trial, including the qualitative sub-
study, was approved by the North-West Research Commit-
tee (Liverpool West), approval number 11/H1002/10. Below,
data are tagged with the participant’s treatment arm (M
for MDI, P for pump), identifying number and interview
round (e.g. M7.2 refers to the second interview with MDI
participant 7).
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45 people were recruited but 3 could not be contacted for
follow-up interviews; hence, the final sample comprised 42
participants of whom 23 were pump and 19 MDI users – see
Table 1. Of these, 36 (86%) reported using their bolus advisors
in their baseline interviews, with 32 (76%) still using them 6
months later. Below, we consider the perspectives and
experiences of those who chose to use advisors and how
their use of advisors changed over time, before outlining why
some people decided not to use, or stopped using, this
technology. As key findings cut across pump and MDI users’
accounts, data from these two participant groups are reported
together.
3.1. Baseline accounts
3.1.1. Motivations for and perceived benefits of using advisors
Participants reported a variety of reasons for using their
advisors and associated benefits, which broadly cohered into
three categories. Participants (n = 14) who considered them-
selves to have poor mathematical skills highlighted a gratitude
for, and reliance on, their advisors from the outset: ‘‘Because I
was the worst, I was terrible at maths at school, I rely on it’’
(M10.1); ‘‘I absolutely live by that machine; it’s fantastic, it’s
been invaluable’’ (M8.1). Indeed, these participants, who were
mostly older/retired and from unskilled or semi-skilled
occupational groups, questioned how they would have
successfully implemented a FIIT regimen without access to
this technological support:
‘‘I mean, for example, this morning my blood was 10 and I
knew I was having a bowl of quick porridge, that’s 3 units,
so I had the six for the three lots of carbs, and then it, my
machine said you need 2, 2 more units, so I had 8 this
morning, I don’t know how I would have managed to work
that out.’’ (M8.1)
Other participants (n = 17) who expressed greater confi-
dence in their mathematical skills described choosing to useTable 1 – Demographic characteristics, diabetes preva-
lence and glycaemic indicators of 42 adult patients.
Age (years) 41.3  12.5; range 24–66
Gender (%) 47.6% female
Diabetes duration
at baseline (years)
17.8  12.9; range 1–41
Occupation
(% at baseline)
-Professional 31
-Semi-skilled 36
-Unskilled 9.5
-Student 7
-Unemployed 16.5
HbA1c (mmol/l,
IFCC; %, NGSP)
Baseline 71  14, range
46–104; 8.6  1.3,
range 6.4–11.7advisors because they saved time and effort: ‘‘it just makes it
less work, to be honest’’ (M20.1); ‘‘I’m just lazy with the maths
really. I don’t want to be working that stuff out, so if it’s going
to do it for me, that’s fine, it’s much easier to let it do it’’ (P23.1).
In addition, by virtue of being fast and easy to use, these
participants described bolus advisors as facilitating accurate
determination of doses when they experienced poor concen-
tration due to hypo or hyperglycaemic excursions. As a
consequence, participants worried less about miscalculating
doses:
‘‘Cos, like I’ve just said, if I were running 4 points high, I’d be
trying to think back, how many units I need and then you
start getting flustered, and start trying to, which makes you
worse, your sugars are going up, and because your sugars
are high you start feeling ratty anyway, and then you start
thinking ‘‘Oh, I can’t work this out’’ so you dial too many on
then, before you know it, your sugars have dropped.’’
(P30.1)
The remaining participants (n = 5) claimed their primary
reason for using their advisors was because they had a data
storage facility:
‘‘because I’m on a 1:1 ratio it’s pretty simple. . . I mean the
main reason I’m using it is because when I get round to
downloading my results onto my laptop or whatever, it will
offer me more information, it has all my dosages and
carbohydrates on there as well.’’ (M15.1)
Hence, as M15 further suggested, using a paper diary,
which would have been more burdensome and time-consum-
ing, was not necessary.
3.1.2. Initial experiences of using advisors and calculating
doses
With the exception of those who highlighted very poor
mathematical skills, participants, at baseline, described
undertaking their own mental or manual calculations
alongside using their advisors, because as P4 pointed out,
‘‘I don’t want to rely on something to do the maths, I try to
work it out myself first and then just check it against the
wizard’’ (P4.1), or, as P43 suggested, because, ‘‘I don’t quite
trust it yet, won’t accept what it says for truth sort of thing. I
always make the measurements in my head, just to be sure
it’s right’’ (P43.1).
In general, participants claimed to agree with, and adminis-
ter, the recommended doses. However, several (n = 12)
highlighted occasions when they had made slight adjustments
to take account of planned physical activity or because the blood
glucose targets they were aiming for were higher or lower than
those programmed in during their courses:
‘‘If it gives me 6.5 and I think to myself I’m going to go and
sort the shed out and all that, 0.5 might be a bit too much.
So I tend to, I might take 6, and I think well, if it’s a little bit
higher in an hour and a half, I can do a correction.’’ (P26.1)
‘‘The only time I’ve not taken its advice has been at bedtime
when I’ve been high and it’s told me to take 2 units, I’ve
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hypos.’’ (M10.1)
3.2. Six month accounts
3.2.1. Dependency and deskilling
Participants with poor mathematical skills reported an on-
going and heavy dependence on their advisors at 6 months, a
situation which became apparent when equipment broke or
was misplaced, with individuals reporting being ‘‘absolutely at
a loss’’ (M14.2). Amongst other participants, there were
notable changes in how they used their advisors over time.
While some (n = 6) continued to do their own calculations,
the majority, like M13, who had initially ‘‘double-checked
everything’’, discussed how, ‘‘lately I don’t do any calculations
at all’’ (M13.2). As these participants suggested, having access
to technology which was fast and easy to use had led to their
becoming ‘‘lazy’’ (P39.2) and to their administering the doses
recommended by their advisors in increasingly unreflective
and unquestioning ways:
‘‘It probably does make you lazy, because I don’t really have
to think about it much, you know, you can do your blood
and then put in what you’re having, have a quick look at it
and not really think any more about it.’’ (P39.2)
‘‘I’ll click it and I enter the amount of carbs and that’s it, I
just go with whatever the wizard tells me, without really
thinking about it.’’ (P31.2)
By virtue of no longer doing their own calculations,
participants also described how easy it was to forget what
their ratios actually were: ‘‘the only thing I could forget is the
ratios of DAFNE, but the machine knows that’’ (M9.2); ‘‘they’re
not in my mind but they’re programmed into the machine’’ (M
9.2). Hence, these participants had inadvertently become
dependent on their advisors to determine their doses for them.
3.2.2. Impact on disease self-management
In some cases (n = 14), reliance on an advisor and/or
unreflective practices of administering ‘‘whatever the wizard
tell me’’ were later found to have had a detrimental impact on
glycaemic control. This included, P2, who described recently
attending a routine diabetes review appointment where, ‘‘they
found out I was having readings of 20 and 25 [mmol/l] and they
got in touch with [course educator] and she hauled me in and
had a look at the machine and altered it [ratio], from 1:1 to one
and a half to one’’ (P2.2). Likewise, P3, who had ‘‘always
followed what it [advisor] is suggesting’’ described how, over a
period of several months, he had had to ‘‘give myself an extra 2
or 3 [units] every other hour to try and bring it down late
morning.’’ This problem was not identified and addressed
until P3 attended a 6 month trial data collection appointment
where, with input from educators, his morning mealtime ratio
was changed.
Only a minority of participants (n = 3) reported having
independently altered their ratios since their courses. In most
cases, as P2 or P3 reported above, if changes had needed to be
made, these had not occurred until a routine diabetes review
or trial follow-up appointment. In most cases, participants
implicated a lack of confidence, poor analytical skills, and/ordeferential attitudes towards health professionals to account
for not considering or making any independent adjustments:
‘‘I suppose I’m kind of subconsciously waiting for somebody
with more expertise to sit down with me and suggest these
changes’’ (M13.2); ‘‘I’m the kind of person that, as I said, I don’t
like to do stuff on my own, I’m afraid in case I do something
wrong and I don’t want to go hypo’’ (P24.2).
However, participants also implicated their bolus advi-
sors. Some (n = 6), for instance, reported not knowing how to
change the settings on their advisors, and, hence, described
leaving their ratios unchanged until they received health
professional input. Others (n = 8) shared a misperception
that, by virtue of being pre-programmed into their advisors
at the time of their courses, their ratios and targets would
never need to be altered: ‘‘well, it’s permanently pro-
grammed into the software . . . so I’d just assumed that
everything would stay the same’’ (P27.2); ‘‘I haven’t ever
changed it [ratio settings] because it was set up for me and I
thought that was it’’ (P42.2). Hence, when these participants
did identify or attempt to address problems with their blood
glucose readings, they focused on physical activity patterns
or on altering background/basal doses: ‘‘it’s your basal’s that
going to have to be tweaked. . . cos your bolus, I don’t really
think you have to tweak’’ (M18.2). Poor recollection of ratios
and/or targets by virtue of them being pre-programmed was
also implicated by some individuals (n = 11): ‘‘they’re
[targets] not in my mind, they’re programmed into the
machine, hence I wouldn’t know what numbers are [in order]
to change them’’ (M14.2).
Furthermore, whilst during their courses, participants kept
a manual (diary) record of the blood glucose readings and
other data (e.g. carbohydrate portions consumed) and received
training on how to review these data in order to adjust their
ratios and other parameters, many described manual record
keeping as burdensome. Hence, the majority (n = 27) reported
how, over time, they had taken advantage of, and become
reliant on, the data storage facilities on their advisors: ‘‘I’m
basically now entering everything into the advisor rather than
writing stuff down’’ (M13.2). However, use of this automated
feature, as such participants further reflected, also resulted in
them reviewing their data less frequently, and sometimes not
all: ‘‘I haven’t looked at the data really’’ (M13.2); ‘‘Um, I’m
relying too much on the meter’s memory for that rather than
making a record and going through it, trying to figure out
patterns’’ (M16.2). Hence, it was not until a review appoint-
ment was attended that individuals, such as M13, actually
recognised that there was problem with their blood glucose
readings which required a ratio or other parameter to be
changed:
‘‘since the course I’ve never once set down and looked at
the data myself so the meeting [6 month follow-up] was the
first time I actually saw the data, and things were. . .the
figures weren’t as good as I anticipated.’’ (M13.2)
3.2.3. Reasons for stopping/never starting
While two participants chose not to use an advisor from the
outset because they were worried it would deskill and
disempower them: ‘‘I did feel like it was talking the control
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the principles and then it’s suddenly said, ‘now forget about
that; the machine will do it for you’’’ (P28.1), the remainder
(n = 4) highlighted practical and logistical reasons. This
included a couple of MDI users who discussed how they
had preferred their old metres, which did not have built-in
advisors, because they were smaller, lighter and hence easier
to transport: ‘‘I know this is quite silly but it’s too big for me, I
feel I already carry so much in my bag’’ (M22.1).
Some participants (n = 2) reported stopping using their
advisors because they did not know how to change the
settings or they found data entry too time-consuming and
burdensome:
‘‘you know it takes quite a long time to type all the numbers
in and it’s quite fiddly and stuff. I just want to do a blood
test, see what I am, wallop some insulin in . . .I think if I used
it, I would get tighter control. It’s just that, in using it, it
interferes with life more than I want it to. It would be, you
know, a frequent inconvenience’’ (M32.2).
A few (n = 2) also discontinued use in light of their
experiences of administering recommended doses, observing
repeated high or low blood sugar levels and, hence, losing trust
in the technology:
‘‘It was calibrated to a certain level, that other meter I got,
you know, they did your carbohydrates and then your
insulin and I kept questioning it and thinking ‘‘something’s
not right here, I knew in my head if I give myself 2 [units]
and my sugar’s nine and a half, I’m going to end up
hypoing. . . so I lost faith in it and I stopped using it.’’ (M29.2)
4. Discussion
This is the first study to explore in-depth and over time
people’s experiences of using bolus advisors. Our findings
suggest that most people, if given access to advisors, use them
and perceive this technology as being beneficial. Not only did
bolus advisors ease the burden of determining bolus doses, in
many cases, a perceived benefit was that advisors eased the
burden of data recording. Amongst participants who ques-
tioned their mathematical ability or whose concentration
could be compromised by high/low blood glucose, use of
advisors also offered reassurance that they were administer-
ing correctly calculated doses.
Hence, these findings lend support to earlier survey work
which found improved overall wellbeing, confidence in dose
determination and treatment satisfaction amongst people
using bolus advisors [6,11,13]. However, by focusing on
individuals’ everyday experiences of using advisors and
following the same people up over time, our findings suggest
that there may be unintended and erstwhile unrecognised,
adverse consequences to giving people access to this
technology. Very few participants reported independently
reviewing and altering their ratios and blood glucose targets
over the 6 months of study, and, in some cases, this was
described as having led to periods of poor glycaemic control.In keeping with findings from earlier qualitative work
undertaken with people on FIIT regimens who were not
using advisors and who had received DAFNE training [5,19],
participants in the current study implicated lack of confi-
dence and/or deferential attitudes to health professionals.
However, our findings also suggest that use of bolus advisors
may reinforce some of the problems encountered. Specifical-
ly, we have seen how some people simply did not know how to
change the settings on their advisors, whereas others
reported a (mis)conception that, by virtue of individual
parameters being pre-programmed, these would never need
to be altered. Follow-up of individual participants has also
highlighted how, by virtue of allowing advisors to do the
calculations for them, people could become ‘deskilled’ and
forget what their ratios actually were (which increased their
reliance on their advisors), and administer doses in increas-
ingly unreflective ways.
An additional area of concern is how participants’ use of
the data storage facilities on their advisors could result in their
not reviewing their data, which mitigated their identifying
problems and patterns in readings which could prompt them
to adjust their parameters and/or seek health professional
advice. Thus the data suggest that use of bolus calculators may
undermine one of the underlying principles of DAFNE and
similar programmes; namely, that patients should reflect on
diary recordings of their blood glucose and carbohydrate
intake to make adjustments to insulin doses in order to
maintain pre-prandial glucose targets.
These findings suggest that, to promote effective use of
advisors, people would benefit from on-going education and
input from health professionals themselves trained in use of
bolus advisors to remind them of the principles of use and to
help ensure the correct ratios and parameters are pro-
grammed in and being used. Health professionals could also
use their contacts with patients to address any misperceptions
individuals might have about ratios and other settings never
needing to be changed. However, given that health profes-
sional input is a costly option, consideration could also be
given to developing and offering people more technologically
advanced advisors, which contain pattern recognition soft-
ware, which could offer prompts and alerts when problems
with blood glucose control occur which patients may
themselves fail to recognise. One component of acceptability
of technology is trust [20,21]. If a device gives incorrect advice
then an individual is less likely to trust it, and may stop using
it, when in fact they could be prompted to re-examine their
settings. As with many healthcare-related technological
devices, bolus advisors may be of more use if real-time
feedback was made available, analytics were more clinically
meaningful [22] and if they included decision support
capabilities [23].
The accounts of those who chose not to use their advisors
also provide useful insight into how equipment might be
improved. This includes making the devices used by those on
MDI regimens compact and light-weight so they are easy to
transport or incorporating advisor technology into devices
individuals already use, such as mobile phones. Given that
some people conveyed difficulties manually entering data into
their advisors, they might also benefit from having access to
voice recognition software.
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research which has reported clinical benefits amongst people
on pump and MDI regimens who use advisors. In the studies
undertaken by Klupa et al. and Shashaj et al., the duration of
follow-up was extremely limited – 7 days and 2 weeks
respectively [8,9]. In addition, in both studies, physicians set
individual parameters into the advisors. Garg et al. and
Ziegler et al. followed patients up for considerably longer (one
year and 6 months respectively), but not only did these
patients receive regular and intensive input and support over
the period of follow-up, they also had their parameters
programmed into their advisors by health professionals at
initial and follow-up visits [10,11]. Given the findings reported
in this study, we would question whether the same
improvements in blood glucose levels and/or glycaemic
control would have been observed if patients had been
followed up for longer and with less intensive health
professional input.
A key study strength is the use of an open-ended,
longitudinal, exploratory design as this has enabled us
identify a number of potentially important issues relating
to bolus advisor usage which have not been recognised or
reported in previous (quantitative) research. An additional
strength is the inclusion of people on both pump and MDI
regimens, which increases the potential generalisabilty of our
findings, not least because key issues cut across both groups.
A potential limitation is that we did include health profes-
sionals in our study. Our participants’ accounts suggest that
they have been inadequately supported by their routine
health care providers after completion of their DAFNE course,
possibly because these professionals lacked knowledge and
understanding of bolus advisor technology. Hence, future
research exploring what the issues are for health profes-
sionals and how they might be better trained and supported
to support patients in using advisors could be considered.
Furthermore, since we used a qualitative approach, our study
was, by design, small-scale. Hence, to better determine the
extent of the issues and potential problems identified in our
study we would recommend a larger scale, longitudinal,
quantitative study be undertaken with patients who use
bolus advisors in a variety of health care settings. Longer-
term follow-up of participants could also be considered to
establish and explore whether the issues identified in this
study extend over time.
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